Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Total Debt (2016 - 2025)

Historic Total Debt for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $34.0 million.

  • Harvard Bioscience's Total Debt fell 1027.79% to $34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.0 million, marking a year-over-year decrease of 1027.79%. This contributed to the annual value of $37.0 million for FY2024, which is 107.49% up from last year.
  • Harvard Bioscience's Total Debt amounted to $34.0 million in Q3 2025, which was down 1027.79% from $34.9 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Total Debt registered a high of $49.3 million during Q3 2022, and its lowest value of $34.0 million during Q3 2025.
  • Its 5-year average for Total Debt is $41.3 million, with a median of $41.4 million in 2023.
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 1238.5% in 2022, then tumbled by 2191.4% in 2023.
  • Over the past 5 years, Harvard Bioscience's Total Debt (Quarter) stood at $48.3 million in 2021, then dropped by 3.12% to $46.8 million in 2022, then decreased by 21.91% to $36.6 million in 2023, then rose by 1.07% to $37.0 million in 2024, then fell by 8.09% to $34.0 million in 2025.
  • Its last three reported values are $34.0 million in Q3 2025, $34.9 million for Q2 2025, and $36.0 million during Q1 2025.